Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | TPI1 | P60174 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MVD | P53602 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026490 | 0.88 | SMN1; SMN2 (0.44) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL18702457 | 0.88 | SMN1; SMN2 (0.44) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23671717 | 0.87 | LPAR3 (0.45) | LPAR2LPAR1ENPP2LPAR3CA12 | |
| SCHEMBL19927107 | 0.84 | LPAR3 (0.52) | LPAR2LPAR1ENPP2LPAR3CA12 | |
| SCHEMBL19926726 | 0.84 | LPAR3 (0.52) | LPAR2LPAR1ENPP2LPAR3CA12 | |
| SCHEMBL6514099 | 0.84 | LPAR3 (0.52) | LPAR2LPAR1ENPP2LPAR3CA12 | |
| SCHEMBL17753845 | 0.80 | LPAR1 (0.46) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL17758486 | 0.78 | LPAR2 (0.45) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23294899 | 0.78 | LPAR2 (0.49) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23294898 | 0.77 | LPAR2 (0.48) | LPAR2LPAR1ENPP2TPI1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010011815-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4376893-A2 | PHOSPHATE PRODRUGS OF CANNABINOIDS | Emory University (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11883500-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | MERCK SHARP & DOHME LLC (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3407916-B1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-10869929-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | MERCK SHARP & DOHME CORP. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190030171-A1 | PHOSPONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3407916-A2 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2018045245-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2017132103-A2 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | disclosed |
| US-5411967-A | Antiinflammatory, immunosuppressant, antitumor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | LPAR2 192/4885LPAR1 169/4885ENPP2 101/4885 |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | LPAR2 1320/4885LPAR1 1096/4885ENPP2 216/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | LPAR2 3348/4885LPAR1 2897/4885ENPP2 1807/4885 |
| US-11883500-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | PHOSPHO1, TK1, MSN | LPAR2 820/4885LPAR1 671/4885ENPP2 389/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | LPAR2 3661/4885LPAR1 3942/4885ENPP2 1316/4885 |
| US-20190030171-A1 | PHOSPONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | PHOSPHO1, PHPT1, PSPH | LPAR2 774/4885LPAR1 621/4885ENPP2 98/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | LPAR2 3847/4885LPAR1 3711/4885ENPP2 2509/4885 |
| US-10869929-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | PHOSPHO1, TK1, MSN | LPAR2 820/4885LPAR1 671/4885ENPP2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.